We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 13, 2021

Edoxaban vs VKA for Atrial Fibrillation After TAVR

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Edoxaban Versus Vitamin K Antagonist for Atrial Fibrillation After TAVR
N. Engl. J. Med 2021 Aug 28;[EPub Ahead of Print], NM Van Mieghem, M Unverdorben, C Hengstenberg, H Möllmann, R Mehran, D López-Otero, L Nombela-Franco, R Moreno, P Nordbeck, H Thiele, I Lang, JL Zamorano, F Shawl, M Yamamoto, Y Watanabe, K Hayashida, R Hambrecht, F Meincke, P Vranckx, J Jin, E Boersma, J Rodés-Cabau, P Ohlmann, P Capranzano, HS Kim, T Pilgrim, R Anderson, U Baber, A Duggal, P Laeis, H Lanz, C Chen, M Valgimigli, R Veltkamp, S Saito, GD Dangas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading